Esperion Therapeutics (ESPR) Gains from Investment Securities (2012 - 2020)

Esperion Therapeutics has reported Gains from Investment Securities for 9 years, with the latest figure at $4.6 million in Q2 2020.

• For the quarter ending Q2 2020, Gains from Investment Securities fell 14.0% year-over-year to $4.6 million; the trailing twelve-month figure through Jun 2020 stood at $4.6 million (down 14.0% YoY), and the FY2025 full-year result was $612000.0, changed N/A from the prior year.
• Gains from Investment Securities for Q2 2020 stood at $4.6 million, down from $4.8 million in the prior quarter.
• The five-year high for Gains from Investment Securities was $5.3 million in Q2 2019, with the low at $13063.0 in Q1 2016.
• Historically, Gains from Investment Securities has averaged $2.7 million across 5 years, with a median of $3.2 million in 2016.
• Annual changes were most pronounced in 2016 — Gains from Investment Securities slumped 99.42% — and 2017, when it jumped 6590.63%.
• Esperion Therapeutics' Gains from Investment Securities stood at $3.3 million in 2016, then grew by 27.74% to $4.2 million in 2017, then increased by 27.52% to $5.3 million in 2018, then decreased by 11.8% to $4.7 million in 2019, then decreased by 2.14% to $4.6 million in 2020.
• The last three Gains from Investment Securities figures came in at $4.6 million (Q2 2020), $4.8 million (Q1 2020), and $4.7 million (Q4 2019), per Business Quant data.